Aligos Therapeutics Inc. Common Stock (ALGS)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor in the Graham and Buffett tradition, and Aligos Therapeutics does not fit my usual hunting ground. It is a clinical-stage biopharmaceutical company with 82 employees, chasing treatments for liver and viral diseases, including ALG-055009 in Phase 2a for MASH and obesity and pevifoscorvir sodium in Phase 2B. That is promising science, but science is not a durable competitive moat until approved and commercialized. The filed numbers show why. In FY2023 revenue was $6.2M, in FY2024 it was $3.6M, and in FY2025 it was $2.2M—shrinking, not compounding. Net losses were $87.7M in FY2023, $131.2M in FY2024, and $24.2M in FY2025. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $2.8M and net loss was $23.0M; in fiscal Q2 2026, ended 2026-06-30, net loss was $1.5M and diluted EPS was $-0.14, with no revenue reported in the filing. Trailing free cash flow is -$94.5M, a -164.5% FCF yield against a $57.5M market cap at the 2026-10-13 close. FairStock calculations show P/B 1.08, P/E -0.71, ROE -113.59%, ROCE -49.12%, Piotroski 3/9, and Altman Z-Score -12.14. Low debt to equity of 0.11 helps, but cash burn is the real enemy. The price is near book value, but that book value is being consumed. Without profits, recurring revenue, or a clear margin of safety, this is speculation on clinical outcomes, not a Buffett-style business.

In plain English: Aligos Therapeutics is a small clinical-stage drug company working on liver and viral diseases. It has no profits, burns a lot of cash, and its revenue has been tiny and shrinking in recent years, so the business looks financially weak. At $5.51 at the 2026-10-13 close, the stock trades near its accounting book value, but because losses are large and recurring, the price does not look clearly cheap or safe.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer